S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SNDX Syndax Pharmaceuticals Inc

14.36

0.08 (0.56%)

29 Jan 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals Inc News

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Thursday 23 January 2025 (6 days ago) • Edgar (US Regulatory)

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Thursday 16 January 2025 (2 weeks ago) • PR Newswire (US)

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Monday 13 January 2025 (2 weeks ago) • PR Newswire (US)

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Wednesday 8 January 2025 (3 weeks ago) • PR Newswire (US)

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Tuesday 7 January 2025 (3 weeks ago) • PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Saturday 4 January 2025 (4 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Saturday 21 December 2024 (1 month ago) • Edgar (US Regulatory)

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Monday 9 December 2024 (2 months ago) • PR Newswire (US)

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Sunday 8 December 2024 (2 months ago) • PR Newswire (US)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 7 December 2024 (2 months ago) • Edgar (US Regulatory)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Wednesday 4 December 2024 (2 months ago) • PR Newswire (US)

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Wednesday 27 November 2024 (2 months ago) • PR Newswire (US)

More Syndax Pharmaceuticals Inc News Articles

Verizon Communications

JP Morgan Chase

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions